Avidity Biosciences, Inc.

NasdaqGM:RNA Stock Report

Market Cap: US$3.8b

Avidity Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:RNA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
22 Aug 24BuyUS$233,989,679RTW Investments, LPCompany5,129,103US$45.62
22 Aug 24SellUS$532,814,925RTW Investments, LPCompany11,425,730US$46.63
18 Jun 24SellUS$385,972Teresa McCarthyIndividual9,864US$39.13
03 Apr 24SellUS$542,214Arthur LevinIndividual20,000US$27.11
12 Mar 24SellUS$58,102Arthur LevinIndividual2,641US$22.00
26 Jan 24BuyUS$2,152,651RTW Investments, LPCompany207,780US$10.49
22 Jan 24SellUS$16,370Michael MacLeanIndividual1,616US$10.13
22 Jan 24SellUS$20,918Teresa McCarthyIndividual2,065US$10.13
22 Jan 24SellUS$120,173RTW Investments, LPCompany11,700US$10.27

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RNA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders490,9340.374%
Public Companies5,075,3043.86%
VC/PE Firms6,300,4084.8%
Hedge Funds15,007,87011.4%
Institutions104,492,21379.5%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61%.

Top Shareholders

Top 25 shareholders own 92.78% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.1%
FMR LLC
16,848,717US$536.1m4.27%0.03%
8.91%
T. Rowe Price Group, Inc.
10,633,962US$338.4m-2.59%0.03%
8.15%
BlackRock, Inc.
9,726,919US$309.5m12.8%no data
7.73%
The Vanguard Group, Inc.
9,226,884US$293.6m55.2%no data
6.82%
RTW Investments, LP
8,132,870US$258.8m-7.65%3.71%
5.89%
Wellington Management Group LLP
7,030,949US$223.7m84.9%0.03%
5.76%
Avoro Capital Advisors LLC
6,875,000US$218.8m5.69%3.01%
5.28%
RA Capital Management, L.P.
6,300,408US$200.5m16.7%2.44%
4.25%
Bristol-Myers Squibb Company
5,075,304US$161.5m0%no data
4.1%
Janus Henderson Group plc
4,896,166US$155.8m33.9%0.06%
3.94%
State Street Global Advisors, Inc.
4,706,106US$149.7m41.8%0.01%
2.58%
Adage Capital Management, L.P.
3,079,374US$98.0m-9.35%0.17%
2.17%
Geode Capital Management, LLC
2,585,303US$82.3m14.6%0.01%
1.75%
Casdin Capital, LLC
2,084,841US$66.3m0%4.28%
1.45%
Tavistock Life Sciences
1,727,388US$55.0m0%3.78%
1.29%
Polar Capital Holdings Plc
1,542,126US$49.1m38.4%0.17%
1.21%
Artal Group S.A.
1,440,736US$45.8m120%1.35%
1.11%
Artisan Partners Limited Partnership
1,329,279US$42.3m-30.1%0.03%
1.04%
Bank of America Corporation, Asset Management Arm
1,238,732US$39.4m647%0.01%
0.93%
D. E. Shaw & Co., L.P.
1,108,647US$35.3m50%0.05%
0.88%
Cormorant Asset Management, LP
1,050,000US$33.4m147%1.8%
0.88%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
1,047,953US$33.3m-12.6%0.01%
0.88%
OrbiMed Advisors LLC
1,044,805US$33.2m47.9%0.46%
0.83%
Charles Schwab Investment Management, Inc.
990,182US$31.5m24.9%0.01%
0.81%
Northern Trust Global Investments
971,131US$30.9m27.8%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 12:46
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Avidity Biosciences, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Tazeen AhmadBofA Global Research
Eric SchmidtCantor Fitzgerald & Co.